ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device
ENDRA Life Sciences Inc. announced the results of a multi-site clinical validation for its TAEUS® Liver device, demonstrating strong concordance with MRI-PDFF and high reproducibility across clinical sites, based on data from 64 patients in the U.S. and Canada. This validation supports the device’s utility in the early detection and monitoring of steatotic liver disease.
ANN ARBOR, Mich.–(BUSINESS WIRE)—- $NDRA #MASLD–ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an ex